R&D channel feed – Endpoints News

R&D channel feed

#ASCO22: With median durability data, Cullinan aims to 'distinguish itself' from Takeda's Exkivity and J&J's Rybrevant in exon 20 NSCLC

4 years ago

#ASCO22: Unconcerned with later market entry, Arcellx on the up with new BCMA CAR-T data

4 years ago

Can wearables help Parkinson's patients? Verily publishes new data from virtual exams

4 years ago

#ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival

4 years ago

Bioethicists weigh in: Xenotransplantation may be here ‘within the next five years,’ but concerns loom

4 years ago

Immunic shares cut in half as biotech dumps ulcerative colitis after PhII fail

4 years ago

Boehringer Ingelheim inks deal for targeted cancer antibodies from Singapore research org

4 years ago

Despite a PhIII fail, Biogen pushes ALS drug tofersen forward with new analysis in move echoing Aduhelm

4 years ago

Amylyx's ALS drug gets a three-month PDUFA delay, setting up the pivotal decision for September

4 years ago

Gilead poaches new pharma development and manufacturing chief from cell therapy 2.0 player

4 years ago

Civica nabs trial partner as it forges ahead to create more affordable insulins

4 years ago

Centessa axes lead program after a patient in kidney disease safety study is hospitalized

4 years ago

Santhera renegotiates milestone payment, increases liquidity runway into 2023 pending NDA filing

4 years ago

Roche wagers $180M in quick cash on a candidate for best-in-class tumor targeting drug

4 years ago

FDA lifts hold on Legend Biotech's follow-up CAR-T targeting CD4+

4 years ago

Trailing AstraZeneca in lupus, Bristol Myers looks to push TYK2 drug into PhIII trials

4 years ago

Sage and Biogen build out case for depression drug as it passes PhIII test in postpartum women

4 years ago

Sanofi earns breakthrough nod in hemophilia A as it continues to play catch-up with Roche's Hemlibra

4 years ago

Research revamp: UK calls on clinical trial sponsors to shut down trials that aren't viable

4 years ago

Swedish biotech crumbles in face of PhII failure of prostate cancer vaccine

4 years ago

Once again, the FDA is delaying BioMarin’s hemophilia A quest as gene therapy frets simmer

4 years ago

TG Therapeutics gets 3-month punt from FDA for standalone BLA in aftermath of Ukoniq + adcomm withdrawal

4 years ago

Transition to new European clinical trials info system starts slowly

4 years ago

ASCO abstracts mint some early winners, but Iovance, SpringWorks get hit by massive losses

4 years ago

First page Previous page 133 134 135136137 138 139 Next page Last page